Results 81 to 90 of about 6,042 (221)

Long-Term Psoriasis Control with Guselkumab, Adalimumab, Secukinumab, or Ixekizumab in the USA

Dermatology and Therapy, 2023
Background Biologics have revolutionized the management of psoriasis, but response to treatment varies. Loss of treatment efficacy may occur over time, requiring treatment switching or escalation.
Timothy Fitzgerald, Maryia Zhdanava, Dominic Pilon, Aditi Shah, Annalise Hilts, Patrick Lefebvre, Steven R. Feldman   +6 more
doaj   +1 more source

Severe and disseminated atypical mycobacteriosis of the skin under immunosuppression

JDDG: Journal der Deutschen Dermatologischen Gesellschaft, EarlyView.
Veronika Zenderowski, Laura Schreieder, Mark Berneburg, Dennis Niebel, Sebastian Haferkamp, Sigrid Karrer, Konstantin Drexler   +6 more
wiley   +1 more source

Effectiveness, safety and quality‐of‐life effects of guselkumab and ustekinumab in patients with psoriasis: Week 104 results from the non‐interventional, prospective, German multicentre PERSIST study [PDF]

Methods Patients (≥18 years of age) received guselkumab or ustekinumab as per routine clinical practice. Outcomes to W104 were examined separately in guselkumab and ustekinumab recipients. An ad hoc exploratory analysis of outcomes with guselkumab versus
Asadullah, Khusru, Gerdes, Christina Valeska, Gomez, Mario, Hoffmann, Matthias, Korge, Bernhard, Kreimendahl, Fabian, Krüger, N, Mortazawi, Dariusch, Personke, Yvonne, Sticherling, Michael, Tabori, Sarah, Taut, Friedemann, Wegner, Sven   +12 more
core   +1 more source

Neuropsychiatric Outcomes of IL‐17 and IL‐23 Inhibitors in Dermatology: Risks, Benefits, and Clinical Implications

International Journal of Dermatology, EarlyView.
Isabella J. Tan, Alexis Mitelman, Mohammad Jafferany   +2 more
wiley   +1 more source

Comparative analysis of persistence and remission with guselkumab versus secukinumab and ixekizumab in the United States

Journal of Dermatological Treatment
Purpose: Real-world data comparing long-term performance of interleukin (IL)-23 and IL-17 inhibitors in psoriasis are limited. This study compared treatment persistence and remission among patients initiating guselkumab versus IL-17 inhibitors.Methods ...
Maryia Zhdanava, Timothy Fitzgerald, Dominic Pilon, Rachel E. Teneralli, Aditi Shah, Lilian Diaz, Patrick Lefebvre, Steven R. Feldman   +7 more
doaj   +1 more source

A Systematic Literature Review and Bucher Indirect Comparison: Tildrakizumab versus Guselkumab

Journal of Health Economics and Outcomes Research, 2020
# Background Psoriasis is a chronic inflammatory skin condition that impacts quality of life and requires long-term treatment and effective symptom management.
Kristian Garn Du Jardin, Pepi Hurtado Lopez, Mette Lange, Rachael McCool, Silvia Maeso Naval, Sandra Quickert   +5 more
doaj   +1 more source

Microneedle Technology in Psoriasis Management: Mechanistic Insights, Technological Innovation, Clinical Progress, and Challenges

Advanced Healthcare Materials, Volume 15, Issue 10, 13 March 2026.
This review explores the evolving role of microneedle systems in psoriasis management, highlighting their potential for enhanced drug delivery, diagnosis, and disease monitoring. It also discusses unmet clinical needs for psoriasis management and technical challenges, while outlining strategic directions to advance microneedle integration into routine ...
Fatma Moawad, Yasmine Ruel, Roxane Pouliot, Davide Brambilla   +3 more
wiley   +1 more source

From Pharmaceutical to Biophysical Therapies: New Horizons in Inflammatory Bowel Disease Management

JCC Plus, Volume 1, Issue 2, March 2026.
Important limitations exist in the current pharmacological landscape of Inflammatory Bowel Disease (IBD), such as variable response rates and treatment‐limiting adverse effects. In this review, we perform a critical assessment of the current literature on novel multimodal biophysical approaches showing alternative mechanisms of action to, and potential
Benedetta Ricchi, Alejandra A. Carriles, Samuel Elias Pineda Chavez, Stefanos Bonovas, Arianna Dal Buono, Cristina Bezzio, Alessandro Armuzzi, Stefania Vetrano   +7 more
wiley   +1 more source

Sustained response to guselkumab regardless of baseline characteristics in patients with active psoriatic arthritis and inadequate response to TNF inhibitors: results from the phase 3b COSMOS clinical trial

RMD Open
Objectives To prospectively evaluate the effect of guselkumab through 48 weeks across various clinical outcomes in subgroups of patients with psoriatic arthritis (PsA) and inadequate response to tumour necrosis factor inhibitors (TNFi-IR) from the phase ...
Iain B McInnes, Laura C Coates, Philipp Sewerin, Frédéric Lavie, Mohamed Sharaf, Miriam Zimmermann, Michela Efficace   +6 more
doaj   +1 more source

Targeting inflammatory pathways in axial spondyloarthritis. [PDF]

, 2019
The triggers and pathogenesis of axial spondyloarthritis (axSpA) are not yet completely understood. However, therapeutic agents targeting tumor necrosis factor-α and interleukin-17 inflammatory pathways have proven successful in suppressing many of the ...
Furst, Daniel E, Louie, James S
core